title: Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via             suppression of NF-κB‑mediated matrix metalloproteinase-9 expression.
abstract: Bladder cancer is the fourth most common cancer in males and the ninth most             common in females. However, despite the numerous advances made in the past few             decades, the prognosis of patients with bladder cancer remains poor. Metastasis             is one of the major causes of mortality in bladder cancer patients. Therefore,             the inhibition of metastasis is one of the most significant issues in bladder             cancer research. The present study was conducted to evaluate the anti-metastatic             potential of (-)-epigallocatechin gallate (EGCG, the major phytochemical in green             tea) against bladder cancer and its mechanism of action. EGCG efficiently and             dose-dependently inhibited adhesion, migration and invasion of T24 human bladder             cancer cells. Mechanistically, EGCG inhibited phosphatidylinositol 3'-kinase/Akt             activation that resulted in inactivation of nuclear factor-κB (NF-κB) and the             inhibition of the expression of matrix metalloproteinase-9 (MMP-9), ultimately             suppressing invasion and metastasis. These findings suggest that EGCG is a potential             therapeutic candidate against tumor invasion.
authors.affiliation: Department of Urology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, PR China.
authors.forename: Jie
authors.initials: J
authors.lastname: Qin
authors.forename: Yunbin
authors.initials: Y
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Bai
authors.forename: Kai
authors.initials: K
authors.lastname: Yang
authors.forename: Qiqi
authors.initials: Q
authors.lastname: Mao
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Lin
authors.forename: Debo
authors.initials: D
authors.lastname: Kong
authors.forename: Xiangyi
authors.initials: X
authors.lastname: Zheng
authors.forename: Liping
authors.initials: L
authors.lastname: Xie
mesh_terms: D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D015536:Down-Regulation / Q000187:drug effects; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology
chemical_list: D016588:Anticarcinogenic Agents; D005353:Fibronectins; D016328:NF-kappa B; D012333:RNA, Messenger; D002392:Catechin; C045651:epigallocatechin gallate; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D020780:Matrix Metalloproteinase 9